This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chambers, M. A.
Right arrow Articles by Hewinson, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chambers, M. A.
Right arrow Articles by Hewinson, R. G.

 Previous Article  |  Next Article 

Infection and Immunity, December 2000, p. 7094-7099, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Identification of a Mycobacterium bovis BCG Auxotrophic Mutant That Protects Guinea Pigs against M. bovis and Hematogenous Spread of Mycobacterium tuberculosis without Sensitization to Tuberculin

Mark A. Chambers,1 Ann Williams,2 Dolores Gavier-Widén,3,dagger Adam Whelan,1 Graham Hall,4 Philip D. Marsh,2 Barry R. Bloom,5 William R. Jacobs,5 and R. Glyn Hewinson1,*

TB Research Group, Department of Bacterial Diseases,1 and Department of Pathology,3 Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey KT15 3NB, and Research Division2 and Pathology,4 CAMR, Salisbury SP4 0JG, United Kingdom, and Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 104615

Received 24 April 2000/Returned for modification 28 May 2000/Accepted 14 August 2000

Tuberculosis remains one of the most significant diseases of humans and animals. The only currently available vaccine against this disease is a live, attenuated vaccine, bacillus Calmette-Guérin (BCG), which was originally derived from Mycobacterium bovis and despite its variable efficacy is the most widely administered vaccine in the world. With the advent of the human immunodeficiency virus-AIDS pandemic concern has been raised over the safety of BCG. Moreover, since BCG sensitizes vaccinated individuals to the tuberculin test, vaccination with BCG prevents diagnosis of infection in vaccinated individuals. Recently, auxotrophic strains of BCG have been generated by insertional mutagenesis which have been shown to be safer than the parent BCG strain following administration to mice with severe combined immunodeficiency disease. These strains have also been shown to give comparable protection against intravenous and intratracheal challenge of BALB/c mice with M. tuberculosis relative to conventional BCG. Here we report that one of these mutants, a leucine auxotroph of BCG, conferred significant protection of the lungs and spleens of guinea pigs infected with M. bovis and protection of the spleens of guinea pigs infected with M. tuberculosis in the absence of a cutaneous hypersensitivity reaction to tuberculin. Therefore, protective immunity to tuberculosis may, at least in part, be achieved without sensitization to the tuberculin skin test. These results indicate that it may be possible to develop a new generation of vaccines based on BCG that are protective, are safe for use in the immunocompromised, and do not preclude the use of the tuberculin skin test in both humans and animals.

* Corresponding author. Mailing address: TB Research Group, Department of Bacterial Diseases, Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey KT15 3NB, United Kingdom. Phone: (44) 1932 357811. Fax: (44) 1932 357684. E-mail: ghewinson.cvl.wood{at}gtnet.gov.uk.

dagger Present address: Division of Wildlife, SVA (National Veterinary Institute), S-750 07 Uppsala, Sweden.

Infection and Immunity, December 2000, p. 7094-7099, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Tullius, M. V., Harth, G., Maslesa-Galic, S., Dillon, B. J., Horwitz, M. A. (2008). A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG. Infect. Immun. 76: 5200-5214 [Abstract] [Full Text]  
  • Clark, S., Cross, M. L., Nadian, A., Vipond, J., Court, P., Williams, A., Hewinson, R. G., Aldwell, F. E., Chambers, M. A. (2008). Oral Vaccination of Guinea Pigs with a Mycobacterium bovis Bacillus Calmette-Guerin Vaccine in a Lipid Matrix Protects against Aerosol Infection with Virulent M. bovis. Infect. Immun. 76: 3771-3776 [Abstract] [Full Text]  
  • Andersen, C. S., Dietrich, J., Agger, E. M., Lycke, N. Y., Lovgren, K., Andersen, P. (2007). The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis. Infect. Immun. 75: 408-416 [Abstract] [Full Text]  
  • Brown, N., Jacobs, M., Parida, S. K., Botha, T., Santos, A., Fick, L., Gicquel, B., Jackson, M., Quesniaux, V., Ryffel, B. (2005). Reduced Local Growth and Spread but Preserved Pathogenicity of a {Delta}purC Mycobacterium tuberculosis Auxotrophic Mutant in Gamma Interferon Receptor-Deficient Mice after Aerosol Infection. Infect. Immun. 73: 666-670 [Abstract] [Full Text]  
  • Wang, J., Thorson, L., Stokes, R. W., Santosuosso, M., Huygen, K., Zganiacz, A., Hitt, M., Xing, Z. (2004). Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis. J. Immunol. 173: 6357-6365 [Abstract] [Full Text]  
  • Chen, L., Wang, J., Zganiacz, A., Xing, Z. (2004). Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis. Infect. Immun. 72: 238-246 [Abstract] [Full Text]  
  • Young, D. B, Stewart, G. R (2002). Tuberculosis vaccines. Br Med Bull 62: 73-86 [Abstract] [Full Text]  
  • Chambers, M. A., Williams, A., Hatch, G., Gavier-Widen, D., Hall, G., Huygen, K., Lowrie, D., Marsh, P. D., Hewinson, R. G. (2002). Vaccination of Guinea Pigs with DNA Encoding the Mycobacterial Antigen MPB83 Influences Pulmonary Pathology but Not Hematogenous Spread following Aerogenic Infection with Mycobacterium bovis. Infect. Immun. 70: 2159-2165 [Abstract] [Full Text]  
  • Orme, I. M. (2001). The search for new vaccines against tuberculosis. J. Leukoc. Biol. 70: 1-10 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»